TBPH
NASDAQTheravance Biopharma Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$16.93-0.04 (-0.24%)
01:30 PM07:45 PM
News · 26 weeks44-33%
2026-01-252026-07-19
Mix2490d
- Insider14(58%)
- SEC Filings7(29%)
- Earnings2(8%)
- Other1(4%)
Latest news
25 items- INSIDERSEC Form 4 filed by Theravance Biopharma Inc.4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
- INSIDERLarge owner Samaha Eli sold $5,791,555 worth of COM (336,697 units at $17.20) (SEC Form 4)4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
- SECSEC Form DEFA14A filed by Theravance Biopharma Inc.DEFA14A - Theravance Biopharma, Inc. (0001583107) (Filer)
- SECTheravance Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Theravance Biopharma, Inc. (0001583107) (Filer)
- PRTHERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHTTheravance Biopharma shareholders to receive $17.00 per share in cash, representing an equity value of approximately $929 millionTheravance Biopharma shareholders to receive a contingent value right (CVR) entitling them to 80% of net proceeds from any future license, divestiture or other monetization of ampreloxetine within the next ten yearsTransaction follows a comprehensive strategic alternatives review conducted by the Company's Strategic Review Committee and Board of DirectorsTransaction expected to close in the second half of 2026, subject to shareholder approval and customary closing conditionsDUBLIN, June 29, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or
- PRZymeworks to Acquire Theravance Biopharma, Inc.Acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolioAcquisition of Theravance Biopharma at $17 per share is supported by an innovative non-recourse financing structure that enhances shareholder value by minimizing Zymeworks’ net capital at risk Transaction expected to be accretive to earnings and cash flow upon closing. YUPELRI® U.S. profit share and ex-U.S. royalties generate ~$60 million annualised cash flow at current run-rates, with continued expected growthTransaction financed primarily by $350 million non-recourse note secured solely by U.S. YUPELRI® profit s
- INSIDERSVP, DEV & HEAD OF IRE OFFICE Miller Aine was granted 18,750 units of Ordinary Shares, increasing direct ownership by 11% to 196,084 units (SEC Form 4)4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
- SECTheravance Biopharma Inc. filed SEC Form 8-K: Leadership Update8-K - Theravance Biopharma, Inc. (0001583107) (Filer)
- INSIDERSVP, COMM & MEDICAL AFFAIRS Farnum Rhonda sold $218,167 worth of Ordinary Shares (13,314 units at $16.39) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 232,457 units (SEC Form 4)4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
- INSIDERDirector Smaldone Alsup Laurie was granted 6,009 units of Ordinary Shares, increasing direct ownership by 8% to 80,989 units (SEC Form 4)4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
- INSIDERDirector Gray Susannah was granted 6,009 units of Ordinary Shares, increasing direct ownership by 14% to 48,146 units (SEC Form 4)4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
- INSIDERDirector Mitchell Dean J was granted 6,009 units of Ordinary Shares, increasing direct ownership by 7% to 97,213 units (SEC Form 4)4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
- INSIDERDirector O'Connor Donal was granted 6,009 units of Ordinary Shares, increasing direct ownership by 8% to 80,213 units (SEC Form 4)4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
- INSIDERDirector Pakianathan Deepika was granted 6,009 units of Ordinary Shares, increasing direct ownership by 10% to 64,074 units (SEC Form 4)4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
- SECTheravance Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Theravance Biopharma, Inc. (0001583107) (Filer)
- INSIDERCHIEF EXECUTIVE OFFICER Winningham Rick E covered exercise/tax liability with 20,038 units of Ordinary Shares, decreasing direct ownership by 1% to 1,631,056 units (SEC Form 4) to cover withholding tax4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
- INSIDERSVP & CHIEF FINANCIAL OFFICER Sawaf Aziz covered exercise/tax liability with 8,670 units of Ordinary Shares, decreasing direct ownership by 2% to 344,953 units (SEC Form 4) (withholding obligation)4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
- INSIDERSVP, DEV & HEAD OF IRE OFFICE Miller Aine covered exercise/tax liability with 6,827 units of Ordinary Shares, decreasing direct ownership by 4% to 177,334 units (SEC Form 4) to satisfy withholding obligation4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
- INSIDERSVP, GEN COUNSEL AND SECRETARY Grimaud Brett A. covered exercise/tax liability with 8,829 units of Ordinary Shares, decreasing direct ownership by 2% to 363,120 units (SEC Form 4) (withholding tax)4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
- INSIDERSVP, COMM & MEDICAL AFFAIRS Farnum Rhonda covered exercise/tax liability with 5,678 units of Ordinary Shares, decreasing direct ownership by 2% to 245,771 units (SEC Form 4) (withholding tax)4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
- SECSEC Form 10-Q filed by Theravance Biopharma Inc.10-Q - Theravance Biopharma, Inc. (0001583107) (Filer)
- SECTheravance Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Theravance Biopharma, Inc. (0001583107) (Filer)
- PRTheravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYUPELRI® Collaboration Revenue increased 15% year-over-year1, from $15.4 million to $17.7 million, driven by continued Net Sales growth and improved operating leverageAll Hatch-Waxman litigation relating to YUPELRI® has been resolved following settlement with Mankind Pharma in MarchOrganizational restructuring and cost reduction initiatives on track; delivered ~20% reduction in Operating Expenses year-over-year (excluding restructuring items)Q1 2026 TRELEGY net sales, reported by GSK, of $873 million, up 2% year-over-year; high confidence in achieving the $100 million 2026 milestone payment2Strategic Review Committee actively evaluating a range of opportunities to maximize shareholder valueQ
- SECSEC Form DEF 14A filed by Theravance Biopharma Inc.DEF 14A - Theravance Biopharma, Inc. (0001583107) (Filer)
- INSIDERSEC Form 4 filed by Winningham Rick E4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
TBPH FAQ
6 questionsWhat does Theravance Biopharma Inc. do?
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory...Where does TBPH stock trade?
Theravance Biopharma Inc. (TBPH) is listed on NASDAQ.What sector and industry is TBPH in?
Theravance Biopharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about TBPH?
Theravance Biopharma Inc. has had 8 recent analyst actions on file. The most recent action was from Oppenheimer: Perform on 2026-03-05. Recent price targets range from $1000.00 to $2800.00.What companies are similar to TBPH?
Notable peers in the same industry include INVA (Innoviva Inc.), STRO (Sutro Biopharma Inc.), CUE (Cue Biopharma Inc.). Compare TBPH side-by-side with any of them on Quantisnow.How can I track TBPH on Quantisnow?
Quantisnow aggregates Theravance Biopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TBPH to receive live email and push alerts on every new disclosure.